Maternal ABO Blood Groups and the Risk Assessment of Pregnancy Complications
Author Information
Author(s): Than Nandor Gabor, Romero Roberto, Meiri Hamutal, Erez Offer, Xu Yi, Tarquini Federica, Barna Laszlo, Szilagyi Andras, Ackerman Ron, Sammar Marei, Fule Tibor, Karaszi Katalin, Kovalszky Ilona, Dong Zhong, Kim Chong Jai, Zavodszky Peter, Papp Zoltan, Gonen Ron
Primary Institution: Wayne State University, Detroit, Michigan, United States of America
Hypothesis
ABO blood group may affect PP13 bioavailability in maternal blood in normal and disease conditions.
Conclusion
ABO blood group can alter PP13-bioavailability in blood, and adjusting PP13 MoMs to ABO blood group improves the predictive accuracy of this test.
Supporting Evidence
- Women with blood group AB had the lowest serum PP13 in the first trimester.
- PP13-binding was the strongest to blood-group AB erythrocytes and weakest to blood-group B erythrocytes.
- Adjustment of PP13 MoMs to maternal ABO blood group improved prediction accuracy for preeclampsia and IUGR.
Takeaway
The study found that a mother's blood type can change the amount of a protein called PP13 in her blood, which helps predict pregnancy complications.
Methodology
The study analyzed maternal serum PP13 in Caucasian and Hispanic women, examining the relationship between blood groups and PP13 levels.
Potential Biases
Potential bias due to the exclusion of women with certain medical conditions.
Limitations
The study may not account for all confounding factors affecting PP13 levels.
Participant Demographics
Caucasian (n=1078) and Hispanic (n=242) pregnant women.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website